Two hundred and thirty-two strains of Escherichia coli belonging to infantile enteropathogenic serotypes isolated in the United Kingdom during 1980 and 1981 were tested for resistance to 10 antimicrobial drugs. Resistance to one or more drugs was found in 134 (57-8%) of the strains, with resistance to sulphonamides, streptomycin, tetracycline, and ampicillin occurring most commonly. Resistance was transferable in 65 out of 104 resistant strains.
Introduction
Severe outbreaks of infantile enteritis due to enteropathogenic Escherichia coli have occurred in Europe and the United States. Such outbreaks, however, have rarely been reported during the past 10 years: sporadic cases continue to occur, but it is often difficult to assess the importance of enteropathogenic E coli isolated from the stools. The increasing problem of multiple transferable drug resistance among Salmonella and Shigella has been well documented recently, but statistics for E coli are not available.' As part of a continuous surveillance of drug resistance in the Enterobacteriaceae we have studied a sample of strains of enteropathogenic E coli isolated in the United Kingdom.
Methods
Bacterial strains-We examined 232 strains of E coli-isolated in the United Kingdom during 1980 *All these strains were also resistant at 256 mg/I.
tTwenty-eight of these strains were also resistant at 256 mg/I.
Results
Resistance to sulphonamides, streptomycin, tetracycline, and ampicillin occurred most commonly (table) . One hundred and thirty-four strains (57-8 0) were resistant to one or more drugs: 22 strains (9 5%) were resistant to one drug, 27 (11 60) to two, and 85 (3666%) to three or more. Twenty-nine strains (12 o5o) were resistant to chloramphenicol, and all of these were resistant to at least three other drugs.
Of E coli strains isolated in the United Kingdom are drug resistant and that resistance is transferable in more than 60% of these.
The majority of autotransferring resistance plasmids identified were of the B and F compatibility groups. Group B plasmids are particularly common in shigellae and have been observed in strains of Shigella dysenteriae 1 that have caused epidemics in Central America8 and Asia. 9 F-like resistance plasmids are common in salmonellae, and E coli and plasmids of the Flme group have been observed in salmonella strains that have caused outbreaks of gastroenteritis in the Middle East,10 India,1" and southern Europe.1' These findings are a cause for concern not simply because they indicate that the choice of treatment for severe illnesses is limited but also because they suggest the existence of a large pool of drug-resistant organisms in the community. Multiple drug resistance may be transferred in vivo to other pathogenic organisms including those E coli responsible for systemic infections such as neonatal meningitis. Further studies are in progress to determine the prevalence of drug resistance in E coli strains isolated from cerebrospinal fluid.
Introduction
The treatment of patients with end-stage renal failure by haemodialysis has been highly successful. Nevertheless, haemodialysis is expensive and several hundred patients die each year in the United Kingdom because the financial resources to provide treatment are lacking.' 2 In the United States, where there has been a quite lavish allocation of federal resources for dialysis programmes, there is increasing pressure to contain or reduce costs.3 4At the same time most units in the United Kingdom and elsewhere are moving away from the use of the bulky Kiil-type artificial kidneys towards the use of small disposable dialysers, which require less work from staff and patients and take up less space in the home. This means, however, that the dialyser and other disposable equipment become a major revenue cost.
Though considerable savings could be made by reusing these disposable items, this policy has, however, met with resistance from both clinicians and patients on the grounds of safety, efficiency, and convenience. The safety and efficiency of the procedure is now widely accepted both in Europe and in the USA,5 6 but convenience to, and acceptance by, patients has received little attention. Since most patients in the United Kingdom dialyse at home, the success of any policy aimed at more economic use of materials depends on their co-operation. A recent survey of home dialysis practice in our unit has given us the opportunity to examine the extent to which our own policy of reuse is implemented in the home.
Cost benefits of reuse
Single use of a disposable dialyser is expensive, about £1900 a year. Reuse (in our case to a total of six times) dramatically reduces this cost by more than half (figure). It is less commonly recognised that the arterial and venous blood lines, which-with the dialyser-form the extracorporeal circuit, are also expensive. If the dialyser can be reused
